Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...

Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...

First Solar, Inc. FSLR reported third-quarter 2025 earnings of $4.24 per share, which missed the Zacks Consensus Estimate of $4.32 by 1.9%. However, the bottom line increased 45.7% from the prior-year ...

DAYTON – In the first game back from the Maui Invitational, Enoch Cheeks dazzled again with 23 points and the UD men’s basketball team shook off its lingering jet lag to rally past Western Michigan 77 ...

First Solar, Inc. FSLR reported first-quarter 2022 loss of 41 cents per share, which came in line with the Zacks Consensus Estimate. The bottom line deteriorated significantly from the prior-year ...

Trisha Jandoc was an associate writer at CNET covering broadband and everything related to home internet. She graduated from St. John's University with a bachelor's degree in journalism and a focus on ...

Forbes contributors publish independent expert analyses and insights. News and opinion about video games, television, movies and the internet. Epic has pledged $100 million toward building Fortnite ...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...